USD 1.61
(-2.42%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 33.6 Thousand USD | -85.36% |
2022 | 229.6 Thousand USD | -44.7% |
2021 | 415.2 Thousand USD | -30.37% |
2020 | 596.3 Thousand USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | -100.0% |
2017 | 10.59 Million USD | -55.77% |
2016 | 23.96 Million USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | 0.0% |
2000 | - USD | -100.0% |
1999 | 650 Thousand USD | 0.0% |
1998 | - USD | -100.0% |
1997 | 2 Million USD | 0.0% |
1996 | - USD | 0.0% |
1995 | - USD | 0.0% |
1994 | - USD | 0.0% |
1993 | - USD | 0.0% |
1992 | - USD | 0.0% |
1991 | - USD | -100.0% |
1990 | 200 Thousand USD | -92.86% |
1989 | 2.8 Million USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - USD | -100.0% |
2024 Q2 | - USD | 0.0% |
2023 FY | 33.6 Thousand USD | -85.36% |
2023 Q3 | 83.53 Thousand USD | -37.2% |
2023 Q1 | 182.07 Thousand USD | -20.7% |
2023 Q4 | 33.6 Thousand USD | -59.77% |
2023 Q2 | 133.01 Thousand USD | -26.94% |
2022 Q4 | 229.6 Thousand USD | -16.86% |
2022 FY | 229.6 Thousand USD | -44.7% |
2022 Q1 | 368.09 Thousand USD | -11.35% |
2022 Q2 | 322.33 Thousand USD | -12.43% |
2022 Q3 | 276.17 Thousand USD | -14.32% |
2021 FY | 415.2 Thousand USD | -30.37% |
2021 Q2 | 507.09 Thousand USD | -8.21% |
2021 Q3 | 461.35 Thousand USD | -9.02% |
2021 Q1 | 552.41 Thousand USD | -7.36% |
2021 Q4 | 415.2 Thousand USD | -10.0% |
2020 Q1 | 719.87 Thousand USD | 0.0% |
2020 FY | 596.3 Thousand USD | 0.0% |
2020 Q2 | 681.78 Thousand USD | -5.29% |
2020 Q3 | 639.27 Thousand USD | -6.23% |
2020 Q4 | 596.3 Thousand USD | -6.72% |
2019 FY | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2018 FY | - USD | -100.0% |
2018 Q1 | 10 Million USD | -5.59% |
2018 Q4 | - USD | 0.0% |
2018 Q2 | 9.38 Million USD | -6.26% |
2018 Q3 | - USD | -100.0% |
2017 Q4 | 10.59 Million USD | -4.1% |
2017 Q3 | 11.05 Million USD | -50.91% |
2017 Q2 | 22.51 Million USD | -6.45% |
2017 Q1 | 24.06 Million USD | 0.42% |
2017 FY | 10.59 Million USD | -55.77% |
2016 Q4 | 23.96 Million USD | 0.87% |
2016 Q1 | 23.44 Million USD | 0.0% |
2016 Q2 | 23.58 Million USD | 0.6% |
2016 Q3 | 23.76 Million USD | 0.74% |
2016 FY | 23.96 Million USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2003 FY | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2001 Q1 | - USD | 0.0% |
2001 FY | - USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 Q3 | - USD | 0.0% |
2001 Q2 | - USD | 0.0% |
2000 Q4 | - USD | 0.0% |
2000 Q3 | - USD | 0.0% |
2000 FY | - USD | -100.0% |
2000 Q1 | - USD | -100.0% |
2000 Q2 | - USD | 0.0% |
1999 Q2 | - USD | 0.0% |
1999 FY | 650 Thousand USD | 0.0% |
1999 Q3 | - USD | 0.0% |
1999 Q1 | - USD | 0.0% |
1999 Q4 | 650 Thousand USD | 0.0% |
1998 Q4 | - USD | 0.0% |
1998 Q3 | - USD | 0.0% |
1998 Q1 | 1.1 Million USD | -45.0% |
1998 Q2 | - USD | -100.0% |
1998 FY | - USD | -100.0% |
1997 Q2 | - USD | 0.0% |
1997 Q4 | 2 Million USD | 0.0% |
1997 Q1 | - USD | 0.0% |
1997 FY | 2 Million USD | 0.0% |
1997 Q3 | - USD | 0.0% |
1996 FY | - USD | 0.0% |
1996 Q4 | - USD | 0.0% |
1996 Q1 | - USD | 0.0% |
1996 Q2 | - USD | 0.0% |
1996 Q3 | - USD | 0.0% |
1995 Q2 | - USD | 0.0% |
1995 Q4 | - USD | 0.0% |
1995 Q1 | - USD | 0.0% |
1995 FY | - USD | 0.0% |
1995 Q3 | - USD | 0.0% |
1994 Q2 | 500 Thousand USD | 0.0% |
1994 Q1 | - USD | 0.0% |
1994 Q4 | - USD | -100.0% |
1994 FY | - USD | 0.0% |
1994 Q3 | 2 Million USD | 300.0% |
1993 Q1 | - USD | 0.0% |
1993 Q2 | - USD | 0.0% |
1993 Q4 | - USD | 0.0% |
1993 Q3 | - USD | 0.0% |
1993 FY | - USD | 0.0% |
1992 Q1 | - USD | 0.0% |
1992 Q4 | - USD | 0.0% |
1992 Q2 | - USD | 0.0% |
1992 Q3 | - USD | 0.0% |
1992 FY | - USD | 0.0% |
1991 Q3 | - USD | 0.0% |
1991 FY | - USD | -100.0% |
1991 Q1 | 200 Thousand USD | 0.0% |
1991 Q2 | - USD | -100.0% |
1991 Q4 | - USD | 0.0% |
1990 Q1 | 200 Thousand USD | -92.86% |
1990 Q3 | 200 Thousand USD | 0.0% |
1990 Q4 | 200 Thousand USD | 0.0% |
1990 Q2 | - USD | -100.0% |
1990 FY | 200 Thousand USD | -92.86% |
1989 FY | 2.8 Million USD | 0.0% |
1989 Q4 | 2.8 Million USD | 1300.0% |
1989 Q3 | 200 Thousand USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.918% |
Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 99.185% |
SQZ Biotechnologies Company | 27.47 Million USD | 99.878% |
Evofem Biosciences, Inc. | 43.37 Million USD | 99.923% |
Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.887% |
Mesoblast Limited | 118.7 Million USD | 99.972% |
Propanc Biopharma, Inc. | 948.27 Thousand USD | 96.456% |
Genus plc | 233.1 Million USD | 99.986% |
VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 98.853% |
CNBX Pharmaceuticals Inc. | 1.34 Million USD | 97.499% |
Marizyme, Inc. | 18.71 Million USD | 99.82% |
ContraFect Corporation | 2.88 Million USD | 98.834% |
Nymox Pharmaceutical Corporation | 750 Thousand USD | 95.519% |
PsyBio Therapeutics Corp. | 135.48 Thousand USD | 75.196% |
Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 97.676% |
Intellipharmaceutics International Inc. | 2.32 Million USD | 98.555% |
AXIM Biotechnologies, Inc. | 5.65 Million USD | 99.406% |
MultiCell Technologies, Inc. | 202.58 USD | -16489.002% |
Accustem Sciences Inc. | - USD | -Infinity% |
RVL Pharmaceuticals plc | 57.48 Million USD | 99.942% |
EV Biologics, Inc. | 1.49 Million USD | 97.752% |
Q BioMed Inc. | 4.1 Million USD | 99.182% |
Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.898% |
Neon Bloom, Inc. | 630.07 Thousand USD | 94.666% |
Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 97.264% |
Biomind Labs Inc. | 735.54 Thousand USD | 95.431% |
TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
Pharming Group N.V. | 171.54 Million USD | 99.98% |
Oncotelic Therapeutics, Inc. | 12.99 Million USD | 99.741% |
Skye Bioscience, Inc. | 4.61 Million USD | 99.272% |
Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 96.216% |
THC Farmaceuticals, Inc. | 141.51 Thousand USD | 76.253% |
Arch Therapeutics, Inc. | 5.87 Million USD | 99.428% |
IMV Inc. | 28.88 Million USD | 99.884% |
Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -30.666% |
Curative Biotechnology, Inc. | 2.25 Million USD | 98.512% |
GB Sciences, Inc. | 1.75 Million USD | 98.09% |
Alpha Cognition Inc. | 1.22 Million USD | 97.246% |
HST Global, Inc. | 98.31 Thousand USD | 65.819% |
CSL Limited | 12.18 Billion USD | 100.0% |
Halberd Corporation | 150 Thousand USD | 77.596% |
Enzolytics Inc. | 996.33 Thousand USD | 96.627% |
Resverlogix Corp. | 6.49 Million USD | 99.482% |
Affymax, Inc. | - USD | -Infinity% |
SYBLEU INC | 477.5 Thousand USD | 92.962% |
Nuo Therapeutics, Inc. | 255.59 Thousand USD | 86.852% |
argenx SE | 20 Million USD | 99.832% |
MetaStat, Inc. | - USD | -Infinity% |
Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.926% |
Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
Arno Therapeutics, Inc. | - USD | -Infinity% |
RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 98.759% |
GeneThera, Inc. | - USD | -Infinity% |
Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
AVAX Technologies, Inc. | - USD | -Infinity% |
Zenith Capital Corp. | 10.22 Thousand USD | -228.665% |
Genscript Biotech Corporation | 417.73 Million USD | 99.992% |
Ember Therapeutics, Inc. | 200.61 Thousand USD | 83.249% |
Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
Sigyn Therapeutics, Inc. | 2.39 Million USD | 98.598% |
WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 85.344% |
American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.95% |
Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 98.889% |
Adynxx, Inc. | - USD | -Infinity% |
Helix BioMedix, Inc. | - USD | -Infinity% |
GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 90.657% |
VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
Capstone Therapeutics Corp. | 20.32 Million USD | 99.835% |
Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 77.393% |
BioStem Technologies, Inc. | 4.71 Million USD | 99.287% |
ONE Bio Corp. | 19.71 Million USD | 99.83% |
Reve Technologies, Inc. | 250.18 Thousand USD | 86.567% |
Burzynski Research Institute, Inc. | - USD | -Infinity% |
Wesana Health Holdings Inc. | 248.72 Thousand USD | 86.488% |
Agentix Corp. | 50 Thousand USD | 32.788% |
Cell Source, Inc. | 9.25 Million USD | 99.637% |
ProtoKinetix, Incorporated | - USD | -Infinity% |
Regen BioPharma, Inc. | 756.2 Thousand USD | 95.556% |
Regen BioPharma, Inc. | 756.2 Thousand USD | 95.556% |
NovAccess Global Inc. | 2.19 Million USD | 98.472% |
Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.525% |
Itoco Inc. | 228.37 Thousand USD | 85.285% |
Rasna Therapeutics, Inc. | 210.97 Thousand USD | 84.071% |
Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 99.326% |
Kadimastem Ltd | 891.22 Thousand USD | 96.229% |
Oncology Pharma Inc. | - USD | -Infinity% |
Institute of Biomedical Research Corp. | 401.84 Thousand USD | 91.637% |
CytoDyn Inc. | 30.07 Million USD | 99.888% |
Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
NDT Pharmaceuticals Inc. | - USD | -Infinity% |
Mobile Lads Corp. | 484.28 Thousand USD | 93.061% |
NanoSphere Health Sciences Inc. | - USD | -Infinity% |
Qrons Inc. | 351.84 Thousand USD | 90.449% |
Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 99.57% |
Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
Nascent Biotech, Inc. | 122.5 Thousand USD | 72.567% |
Rebus Holdings, Inc. | 310 Thousand USD | 89.159% |
ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 99.29% |
International Stem Cell Corporation | 4.17 Million USD | 99.196% |
Bioxytran, Inc. | 1.92 Million USD | 98.254% |
GlobeImmune, Inc. | - USD | -Infinity% |
Predictive Technology Group, Inc. | - USD | -Infinity% |
ProText Mobility, Inc. | 62.41 Thousand USD | 46.155% |
Cardax, Inc. | - USD | -Infinity% |
VG Life Sciences Inc. | 2.18 Million USD | 98.459% |
Kaleido Biosciences, Inc. | - USD | -Infinity% |
Advaxis, Inc. | 8.31 Million USD | 99.596% |
Adhera Therapeutics, Inc. | 8.58 Million USD | 99.609% |
RenovaCare, Inc. | - USD | -Infinity% |
Regnum Corp. | 1.55 Million USD | 97.84% |
Innovation Pharmaceuticals Inc. | 268 Thousand USD | 87.46% |
Neutra Corp. | 54.15 Thousand USD | 37.946% |
Windtree Therapeutics, Inc. | 1.83 Million USD | 98.164% |
PureTech Health plc | 25.51 Million USD | 99.868% |
Coeptis Therapeutics, Inc. | 1.22 Million USD | 97.255% |
IXICO plc | 472.02 Thousand USD | 92.88% |
IntelGenx Technologies Corp. | 15.5 Million USD | 99.783% |
Gelesis Holdings, Inc. | 62.26 Million USD | 99.946% |
CSL Limited | 12.18 Billion USD | 100.0% |
Cellectis S.A. | 92.77 Million USD | 99.964% |